{"id":535281,"date":"2021-09-07T23:04:13","date_gmt":"2021-09-08T03:04:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/"},"modified":"2021-09-07T23:04:13","modified_gmt":"2021-09-08T03:04:13","slug":"sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/","title":{"rendered":"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, Sept. 7, 2021<\/span> \/PRNewswire\/ —\u00a0Robbins Geller Rudman<\/span> & Dowd LLP<\/b><\/a> announces that purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018<\/span> and August 5, 2021<\/span>, inclusive (the “Class Period”) have until November 1, 2021<\/span> to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals<\/i> class action lawsuit.\u00a0 The Spectrum Pharmaceuticals <\/i>class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934.\u00a0 The Spectrum Pharmaceuticals<\/i> class action lawsuit (Luo v. Spectrum Pharmaceuticals, Inc.<\/i>, No. 2:21-cv-01612) was commenced on August 31, 2021<\/span> and is pending in the District of Nevada<\/span>.<\/p>\n

\n If you wish to serve as lead plaintiff of the <\/b>
\n
\n Spectrum Pharmaceuticals<\/i> class action lawsuit, please provide your information by clicking here<\/a>.\u00a0 You can also contact attorney J.C. Sanchez<\/a> of Robbins Geller by calling 800\/449-4900 or via e-mail at jsanchez@rgrdlaw.com<\/a>.\u00a0 Lead plaintiff motions for the Spectrum Pharmaceutical <\/i>class action lawsuit must be filed with the court no later than November 1, 2021<\/span>.<\/b>\n <\/p>\n

\n CASE ALLEGATIONS<\/b>: Spectrum Pharmaceuticals is a biopharmaceutical company whose products under development include, among others, ROLONTIS (eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia.\u00a0 In December 2018<\/span>, Spectrum Pharmaceuticals submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for ROLONTIS as a treatment for chemotherapy-induced neutropenia (the “ROLONTIS BLA”).<\/p>\n

The Spectrum Pharmaceuticals <\/i>class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the ROLONTIS manufacturing facility maintained deficient controls and\/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum Pharmaceuticals had therefore materially overstated the ROLONTIS BLA’s approval prospects; and (iv) as a result, Spectrum Pharmaceuticals’ public statements were materially false and misleading at all relevant times.<\/p>\n

On August 6, 2021<\/span>, Spectrum Pharmaceuticals announced receipt of a Complete Response Letter (“CRL”) from the FDA regarding the ROLONTIS BLA.\u00a0 The CRL cited deficiencies related to manufacturing and indicated that a reinspection of Spectrum Pharmaceuticals’ manufacturing facility will be necessary.\u00a0 On this news, Spectrum Pharmaceuticals’ stock price fell more than 21%, damaging investors.<\/p>\n

\n THE LEAD PLAINTIFF PROCESS<\/b>: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Spectrum Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals <\/i>class action lawsuit.\u00a0 A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.\u00a0 A lead plaintiff acts on behalf of all other class members in directing the Spectrum Pharmaceuticals <\/i>class action lawsuit.\u00a0 The lead plaintiff can select a law firm of its choice to litigate the Spectrum Pharmaceuticals<\/i> class action lawsuit.\u00a0 An investor’s ability to share in any potential future recovery of the Spectrum Pharmaceuticals<\/i> class\u00a0action lawsuit is not dependent upon serving as lead plaintiff.\u00a0 <\/p>\n

\n ABOUT ROBBINS GELLER RUDMAN & DOWD LLP<\/b>: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions.\u00a0 Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever \u2013 $7.2 billion<\/span> \u2013 in In re Enron Corp. Sec. Litig<\/i>.\u00a0 The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion<\/span> for investors last year, more than double the amount recovered by any other securities plaintiffs’ firm.\u00a0 Please visit http:\/\/www.rgrdlaw.com<\/a> for more information.<\/p>\n

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.<\/p>\n

Contact:<\/p>\n

Robbins Geller Rudman<\/span> & Dowd LLP
655 W. Broadway, San Diego<\/span>, CA\u00a0 92101
J.C. Sanchez, 800-449-4900
jsanchez@rgrdlaw.com<\/a><\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case-301369383.html<\/a><\/p>\n

SOURCE Robbins Geller Rudman & Dowd LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Robbins Geller Rudman & Dowd LLP announces that purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”) have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit.\u00a0 The Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934.\u00a0 The Spectrum Pharmaceuticals class action lawsuit (Luo v. Spectrum Pharmaceuticals, Inc., No. 2:21-cv-01612) was commenced on August 31, 2021 and is pending in the District of Nevada. If you wish to serve as lead plaintiff of the Spectrum Pharmaceuticals class … <\/p>\n

Continue reading “SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535281","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Robbins Geller Rudman & Dowd LLP announces that purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”) have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit.\u00a0 The Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934.\u00a0 The Spectrum Pharmaceuticals class action lawsuit (Luo v. Spectrum Pharmaceuticals, Inc., No. 2:21-cv-01612) was commenced on August 31, 2021 and is pending in the District of Nevada. If you wish to serve as lead plaintiff of the Spectrum Pharmaceuticals class … Continue reading "SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T03:04:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA96347&sd=2021-09-07\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case\",\"datePublished\":\"2021-09-08T03:04:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/\"},\"wordCount\":650,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA96347&sd=2021-09-07\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/\",\"name\":\"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA96347&sd=2021-09-07\",\"datePublished\":\"2021-09-08T03:04:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA96347&sd=2021-09-07\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA96347&sd=2021-09-07\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/","og_locale":"en_US","og_type":"article","og_title":"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Robbins Geller Rudman & Dowd LLP announces that purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”) have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit.\u00a0 The Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934.\u00a0 The Spectrum Pharmaceuticals class action lawsuit (Luo v. Spectrum Pharmaceuticals, Inc., No. 2:21-cv-01612) was commenced on August 31, 2021 and is pending in the District of Nevada. If you wish to serve as lead plaintiff of the Spectrum Pharmaceuticals class … Continue reading \"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T03:04:13+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA96347&sd=2021-09-07","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case","datePublished":"2021-09-08T03:04:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/"},"wordCount":650,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA96347&sd=2021-09-07","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/","name":"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA96347&sd=2021-09-07","datePublished":"2021-09-08T03:04:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA96347&sd=2021-09-07","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA96347&sd=2021-09-07"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sppi-alert-spectrum-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-case\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535281"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535281\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}